cmAngio® vs prolaio eVO2peak Module
AI Verdict
Choose cmAngio® if…
Choose cmAngio® if your clinical practice aims to integrate early cardiovascular risk assessment into routine breast cancer screening programs. This AI-powered tool leverages existing mammogram data to detect Breast Arterial Calcifications (BAC), providing valuable insights into a woman's cardiovascular health without requiring additional radiation or procedures. It is ideal for radiology departments seeking to enhance patient care by offering a dual-purpose screening approach.
View cmAngio® →Choose prolaio eVO2peak Module if…
Choose prolaio eVO2peak Module if you need to longitudinally monitor and estimate peak oxygen consumption (eVO2peak) for cardiovascular research or patient management. This cloud-based software utilizes real-world data from FDA-cleared wearable sensors, offering a non-invasive way to assess functional capacity. It is particularly well-suited for cardiology, physical medicine & rehab, or sports medicine specialists focused on objective, high-density data collection for patient evaluation and progress tracking.
View prolaio eVO2peak Module →Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Quick Comparison
| Feature | cmAngio® | prolaio eVO2peak Module |
|---|---|---|
| Pricing | Paid, out-of-pocket | Contact for pricing |
| Deployment | Cloud-based, integrates with any DICOM-compliant viewer | Cloud-based (software-only, processes remote sensor data) |
| BAA Available | Unknown | Yes AI-estimated |
| FDA Status | Cleared AI-estimated | Cleared AI-estimated |
| HIPAA | Yes AI-estimated | Yes AI-estimated |
Head-to-Head
AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.
Usability
cmAngio®cmAngiou00ae (Tool A) offers quicker and easier installation (less than an hour) and is compatible with any DICOM-compliant viewer, integrating seamlessly into existing radiology workflows. Prolaio eVO2peak Module (Tool B) requires data from qualified third-party wearable sensors, which may introduce additional steps for data collection and integration for the user.
Clinical Value
cmAngio®cmAngiou00ae (Tool A) provides insights into cardiovascular health by detecting Breast Arterial Calcifications (BAC) on routine mammograms, enabling early risk assessment without additional radiation or procedures. This leverages existing imaging data for a novel cardiovascular risk marker. Prolaio eVO2peak Module (Tool B) estimates peak oxygen consumption (eVO2peak) using wearable data, which is also valuable but requires new data streams.
Pricing & Value
TieBoth tools require direct contact with the vendor for pricing details, making a direct comparison of their cost-effectiveness impossible. While Tool A mentions potential 'limited-time offers for no-cost implementation and service,' this is not a guaranteed or transparent pricing structure.
Enterprise Readiness
prolaio eVO2peak ModuleBoth tools are FDA-cleared, HIPAA-compliant, and cloud-based, indicating a strong foundation for enterprise use. However, Prolaio eVO2peak Module (Tool B) explicitly states it 'has_baa: 1', implying a readily available Business Associate Agreement, which simplifies the legal and compliance process for healthcare organizations. cmAngiou00ae (Tool A) requires contacting the vendor for BAA details.
Innovation
cmAngio®cmAngiou00ae (Tool A) demonstrates significant innovation by repurposing routinely collected mammography data to identify a new cardiovascular risk factor (BAC), extending the value of existing clinical workflows. Prolaio eVO2peak Module (Tool B) is also innovative in its use of deep learning with real-world wearable data for eVO2peak estimation, but Tool A's approach to extracting novel insights from established imaging feels particularly groundbreaking.
Support & Docs
TieNeither the provided structured facts nor web searches offer sufficient public detail regarding the specific support structures, documentation availability, or service level agreements for either cmAngiou00ae or Prolaio eVO2peak Module. Both companies indicate contact options for support, but no comparative information is available.
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | cmAngio® | prolaio eVO2peak Module |
|---|---|---|
| Product Name | cmAngiou00ae | prolaio eVO2peak Module |
| Company | CureMetrix | Prolaio |
| Description | FDA-cleared AI software for detecting Breast Arterial Calcifications (BAC) on mammograms, providing insights into cardiovascular health and aiding early risk assessment. | FDA-cleared software to estimate peak oxygen consumption using real-world patient data for cardiovascular research and care. |
| Key Functionality | AI-based detection of Breast Arterial Calcifications (BAC) | Estimates peak oxygen consumption (eVO2peak) |
| Categories | Cardiology AI, OB/GYN AI, Radiology & Imaging AI | Cardiology AI, Clinical Decision Support & Reference |
| Specialties | Cardiology, Obstetrics & Gynecology, Radiology | Cardiology, Physical Medicine & Rehab, Sports Medicine |
Videos
Demos, reviews, and walkthroughs featuring cmAngio® and prolaio eVO2peak Module.